共 92 条
[1]
Watanabe JH(2018)Cost of prescription drug-related morbidity and mortality Ann Pharmacother 52 829-837
[2]
McInnis T(2009)Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability Arthritis Res Ther 11 R26-1464
[3]
Hirsch JD(2019)Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study Lancet 393 1453-2007
[4]
Pascual-Ramos V(2019)Elexacaftor/Ivacaftor/Tezacaftor: first approval Drugs 79 2001-1780
[5]
Contreras-Yanez I(2015)Evidence-based recommendations for the management of comorbidities in rheumatoid arthritis, psoriasis, and psoriatic arthritis: expert opinion of the canadian dermatology-rheumatology comorbidity initiative J Rheumatol 42 1767-1017
[6]
Villa AR(2017)Wellness and the role of comorbidities in multiple sclerosis Neurotherapeutics 14 999-e138
[7]
Cabiedes J(2017)Current and emerging comorbidities in cystic fibrosis Presse Med 46 e125-415
[8]
Rull-Gabayet M(2018)The current status of outcomes-based contracting for manufacturers and payers: an AMCP membership survey J Manag Care Spec Pharm 24 410-1077
[9]
Carrat F(2019)Navigating the wild west of medication adherence reporting in specialty pharmacy J Manag Care Spec Pharm 25 1073-1288
[10]
Hoy SM(2019)Closing the gap: identifying rates and reasons for nonadherence in a specialty population J Manag Care Spec Pharm 25 1282-705